Nova Patents
EP0361908A3

Combination enzyme immunotherapeutics

Abstract

Target cells bearing a distinguishing sur­face antigen may be killed selectively, without harm to bystander cells, by administering myeloperoxidase, eosinophil peroxidase, thyroperoxidase, or salivary peroxidase, conjugated to a binding agent capable of specifically binding said surface antigen, and a hydrogen peroxide-producing enzyme conjugated to a second binding agent. The hydrogen peroxide-produc­ing enzyme, in the presence of its substrate, gener­ates hydrogen peroxide, which is utilized by the per­oxidase to lethally halogenate the target cells.

Term

Term ended

Projected expiry passed 28 September 2009, 17 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

Every citation, both ways

Citations
DocumentRelationOfficeCategoryCited during
WO8703205A1CitesWorld Intellectual Property Organization (WIPO)YDSearch report
BIOCHEMISTRY INTERNATIONAL, vol. 13, no. 2, August 1986, pages 233-243, Academic Press Australia; J. PENE et al.: "In-vitro cytolysis of myeloma tumor cells with glucose oxidase and lactoperoxidase antibody conjugates"Non-patent––Search report
CHEMICAL PATHOLOGY AND PHARMACOLOGY, vol. 6, September 1973, pages 709-717; T.J. SULLIVAN et al.: "Specific killing of parasites by antibody-enzyme conjugates"Non-patent––Search report
J. IMMUNOLOGICAL METHODS, vol. 79, 1985, pages 307-318, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, NL; R.B. LAL et al.: "Selective elimination of lymphocyte subpopulations by monoclonal antibody-enzyme conjugates"Non-patent––Search report